Search Within

Ingo K Mellinghoff

  1. "2016"
Formats
  1. Meeting Abstract (12)
  2. Journal Article (6)
Groups
  1. GSK Faculty (18)
  2. Human Oncology and Pathogenesis Program (18)
  3. Tow Center for Developmental Oncology (TCDO) (18)
  4. Radiology, Department of (7)
  5. Neuroradiology Service (6)
  6. Sloan Kettering Institute Postdocs (4)

More Groups

People
  1. Lisa De Angelis (10)
  2. Antonio Omuro (9)
  3. Elena Pentsova (8)
  4. Christian Grommes (7)
  5. Craig Nolan (7)
  6. Thomas Kaley (7)

More People

Years
  1. 2016 (18)
Publications
  1. Neuro-Oncology (5)
  2. Journal of Clinical Oncology (4)
  3. Annals of Oncology (2)
  4. Blood (1)
  5. Cell Reports (1)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. Oxford University Press (7)
  2. American Society of Clinical Oncology (4)
  3. Amer Soc Clinical Investigation Inc (1)
  4. American Association for Cancer Research (1)
  5. American Society of Hematology (1)
  6. Cell Press (1)

More Publishers

Results (18)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase IB trial of carboxyamidotriazole orotate (CTO) and radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in newly diagnosed glioblastoma (GBM)
    Meeting Abstract

    Omuro, A. M. P.; Beal, K.; McNeill, K. A.; Thomas, A. A.; Lin, X.; Kaley, T. J.; DeAngelis, L. M.; Mellinghoff, I. K.; Diamond, E. L.; Chan, T. A. T.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Multicenter phase IB trial of carboxyamidotriazole orotate (CTO) combined with temozolomide (TMZ) for recurrent glioblastoma (GBM) and other malignant gliomas (MG)
    Meeting Abstract

    Lin, X.; Kaley, T. J.; Pentsova, E.; DeAngelis, L. M.; Daras, M.; Gavrilovic, I. T.; Mellinghoff, I. K.; McKeown, A.; Manne, M.; Hansen, J.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase I study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
    Meeting Abstract

    Grommes, C.; Kaley, T. J.; Nolan, C.; Omuro, A. M. P.; Wolfe, J.; Mellinghoff, I. K.; DeAngelis, L. M.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Single-agent ibrutinib in recurrent/refractory central nervous system lymphoma
    Meeting Abstract

    Grommes, C.; Pastore, A.; Gavrilovic, I.; Kaley, T.; Nolan, C.; Omuro, A. M.; Wolfe, J.; Pentsova, E.; Hatzoglou, V.; Mellinghoff, I.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Are mutations in mismatch repair (MMR) genes our next biomarker of alkylating agent induced hypermutator phenotype? Preliminary results from the Ivy precision trial
    Meeting Abstract

    Kuhn, J.; Chen, R.; Clarke, J.; Chang, S.; Cloughesy, T.; Colman, H.; Wen, P.; Mellinghoff, I.; Ligon, K.; de Groot, J.; more...
    Neuro-Oncology (2016)

    Fulltext@MSK | Save
  • Phase II study of single agent buparlisib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
    Meeting Abstract

    Grommes, C.; Pentsova, E.; Nolan, C.; Wolfe, J.; Mellinghoff, I.; DeAngelis, L.
    Neuro-Oncology (2016)

    Fulltext@MSK | Save
  • Phase I/II study of single agent Ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
    Meeting Abstract

    Grommes, C.; Gavrilovic, I.; Kaley, T.; Nolan, C.; Omuro, A.; Wolfe, J.; Pentsova, E.; Hatzoglou, V.; Mellinghoff, I.; DeAngelis, L.
    Neuro-Oncology (2016)

    Fulltext@MSK | Save
  • AG120, a first-in-class mutant IDH1 inhibitor in patients with recurrent or progressive IDH1 mutant glioma: Results from the phase 1 glioma expansion cohorts
    Meeting Abstract

    Mellinghoff, I. K.; Touat, M.; Maher, E.; DeLaFuente, M.; Cloughesy, T. F.; Holdhoff, M.; Cote, G.; Burris, H.; Janku, F.; Huang, R.; more...
    Neuro-Oncology (2016)

    Fulltext@MSK | Save
  • Identification of RAN binding protein 6 as EGFR feedback regulator and candidate tumor suppressor
    Meeting Abstract

    Hsieh, W.; Oldrini, B.; Erdjument-Bromage, H.; Codega, P.; Vivanco, I.; Rohle, D.; Campos, C.; Bielski, C. M.; Taylor, B. S.; Tempst, P.; more...
    Molecular Biology of the Cell (2016)

    Fulltext@MSK | Save
  • Phase II study of single agent buparlisib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
    Meeting Abstract

    Grommes, C.; Pentsova, E.; Nolan, C.; Wolfe, J.; Mellinghoff, I. K.; Deangelis, L.
    Annals of Oncology (2016)

    Fulltext@MSK | Save